Literature DB >> 19734207

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Robin J Prestwich1, Fiona Errington, Lynette P Steele, Elizabeth J Ilett, Ruth S M Morgan, Kevin J Harrington, Hardev S Pandha, Peter J Selby, Richard G Vile, Alan A Melcher.   

Abstract

Oncolytic virotherapy may mediate antitumor effects via direct oncolysis or immune-mediated tumor regression. Although the ability of oncolytic viruses to generate adaptive antitumor immunity has been characterized, their interactions with the innate immune system are relatively unclear. Using a human in vitro system, this study investigates the innate immunological consequences of reovirus therapy and its potential to activate NK cell-mediated antitumor activity. Dendritic cells (DC) loaded with reovirus-infected human melanoma Mel888 cells (DC-MelReo), but not reovirus-infected tumor cells alone, induced IFN-gamma production within the NK cell population upon coculture with PBMC, in a cell-to-cell contact-dependent manner. DC-MelReo secreted the chemokines CCL2, 3, 4, 5, 7, 8, 11, and CXCL10; these culture supernatants induced NK cell chemotaxis. Coculture of DC-MelReo with purified NK cells induced reciprocal contact-dependent phenotypic DC maturation, while DC-MelReo elicited up-regulation of the activation marker CD69 on NK cells, in a partially contact and partially IL-12 dependent manner. Significantly, DC-MelReo induced NK cell cytotoxicity toward tumor cells by a type I IFN dependent mechanism. These data demonstrate that tumor infection by reovirus can act via DC to induce NK cell recruitment, activation, and cytotoxicity, along with reciprocal DC maturation. These findings suggest that reciprocal DC-NK cell interactions, following reovirus therapy, may play an important role in altering the immune milieu of the tumor microenvironment and mediating tumor regression.

Entities:  

Mesh:

Year:  2009        PMID: 19734207     DOI: 10.4049/jimmunol.0901074

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  Thunder and lightning: immunotherapy and oncolytic viruses collide.

Authors:  Alan Melcher; Kelley Parato; Cliona M Rooney; John C Bell
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

Review 2.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

3.  Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Authors:  Kevin J Harrington; Eleni M Karapanagiotou; Victoria Roulstone; Katie R Twigger; Christine L White; Laura Vidal; Debbie Beirne; Robin Prestwich; Kate Newbold; Merina Ahmed; Khin Thway; Christopher M Nutting; Matt Coffey; Dean Harris; Richard G Vile; Hardev S Pandha; Johann S Debono; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2010-05-18       Impact factor: 12.531

4.  Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.

Authors:  Chandini M Thirukkumaran; Zhong Qiao Shi; Gerard J Nuovo; Joanne Luider; Karen A Kopciuk; Yuan Dong; Ahmed A Mostafa; Satbir Thakur; Kathy Gratton; Ailian Yang; Alex C Chin; Matt C Coffey; Victor H Jimenez-Zepeda; Douglas Stewart; Marta Chesi; P Leif Bergsagel; Don Morris
Journal:  Blood Adv       Date:  2019-03-12

5.  Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Christine Pulido; Diana Rommelfanger; Feorillo Galivo; Karen Kaluza; Timothy Kottke; Jill Thompson; Alan Melcher; Richard Vile
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

6.  Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Authors:  Evanthia Galanis; Svetomir N Markovic; Vera J Suman; Gerard J Nuovo; Richard G Vile; Timothy J Kottke; Wendy K Nevala; Michael A Thompson; Jean E Lewis; Kandelaria M Rumilla; Victoria Roulstone; Kevin Harrington; Gerald P Linette; William J Maples; Matt Coffey; James Zwiebel; Kari Kendra
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

7.  A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Authors:  Douglas W Sborov; Gerard J Nuovo; Andrew Stiff; Thomas Mace; Gregory B Lesinski; Don M Benson; Yvonne A Efebera; Ashley E Rosko; Flavia Pichiorri; Michael R Grever; Craig C Hofmeister
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

8.  Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.

Authors:  Timothy Kottke; John Chester; Elizabeth Ilett; Jill Thompson; Rosa Diaz; Matt Coffey; Peter Selby; Gerard Nuovo; Jose Pulido; Debabrata Mukhopadhyay; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

9.  NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

Authors:  Yotam Bar-On; Yoav Charpak-Amikam; Ariella Glasner; Batya Isaacson; Alexandra Duev-Cohen; Pinchas Tsukerman; Alexander Varvak; Michal Mandelboim; Ofer Mandelboim
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 10.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.